Article · 30 Apr 2025
Review articlePublished 8 Jul 2016
Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Poly(ADP-ribose) polymerase (PARP) inhibitors are currently in development for the treatment of cancer. PARP-1 and PARP-2 are important in the repair of DNA damage. PARP inhibitors used either as single agents or in combination with other cytotoxics, aim to increase efficacy of DNA damage. When PARP is inactivated in cells lacking functional BRCA1 or BRCA2, cells reach a high degree of genomic instability and die. Populations studied in ongoing and reported clinical trials include BRCA mutation-associated cancers, as well as sporadic breast cancers, ovarian cancers and other malignancies. In this review, PARP inhibitors undergoing clinical trial evaluation in humans (olaparib, iniparib, veliparib, rucaparib, MK-4827 and INO-1001) are discussed, with a focus on breast cancer, but also other tumors and the recently reported study results.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Mustafa Khasraw”
- BylineArticles whose byline prints “Mark Robson”